D3697

Sigma-Aldrich

Dipeptidyl peptidase IV Inhibitor III

Sinónimos:
1-(((1-(Hydroxymethyl)cyclopentyl)amino)acetyl)-2,5-cis-pyrrolidinedicarbonitrile, Dipeptidyl peptidase IV Inhibitor III
Empirical Formula (Hill Notation):
C14H20N4O2 · HCl
Peso molecular:
312.80
NACRES:
NA.77

Nivel de calidad

200

ensayo

≥97% (HPLC)

formulario

powder

temp. de almacenamiento

2-8°C

Acciones bioquímicas o fisiológicas

Dipeptidyl peptidase IV is a key enzyme involved in the regulation of incretin hormone levels in the gastrointestinal tract. Incretin hormones, such as glucagon like peptide (GLP-1) and glucose-dependent insulinotopic hormone (GIP) / gastoric inhibitory peptide, cause the glucose stimulated release of insulin. This allows the endocrine system to preemptively stimulate release insulin in response to ingestion of high sugar foods. Type 2 diabetics demonstrate a greatly reduced incretin induced insulin release response.

This response in hyperglycemic conditions is counterbalanced by the rapid rate of degradation of these incretin hormones by dipeptidyl peptidase IV in normal conditions. Inhibition of dipeptidyl peptidase IV results in longer lifetime of the incretin hormones in the GI tract and thus prolonged stimulation of insulin production. Specific dipeptidyl peptidase inhibitors are actively being explored as drug targets for treating type 2 diabetes and several candidates are actively in clinical trial.

Dipeptidyl peptidase IV Inhibitor III is an orally bioavailable dicyanopyrrolidine compound that acts as a slow-binding and active site-targeting inhibitor of Dipeptidyl peptidase IV (IC50 = 106 nM using recombinant human DPP IV
Dipeptidyl peptidase IV is a key enzyme involved in the regulation of incretin hormone levels in the gastrointestinal tract. Incretin hormones, such as glucagon like peptide (GLP-1) and glucose-dependent insulinotopic hormone (GIP) / gastoric inhibitory peptide, cause the glucose stimulated release of insulin. This allows the endocrine system to preemptively stimulate release insulin in response to ingestion of high sugar foods. Type 2 diabetics demonstrate a greatly reduced incretin induced insulin release response.

This response in hyperglycemic conditions is counterbalanced by the rapid rate of degradation of these incretin hormones by dipeptidyl peptidase IV in normal conditions. Inhibition of dipeptidyl peptidase IV results in longer lifetime of the incretin hormones in the GI tract and thus prolonged stimulation of insulin production. Specific dipeptidyl peptidase inhibitors are actively being explored as drug targets for treating type 2 diabetes and several candidates are actively in clinical trial.

RIDADR

NONH for all modes of transport

WGK Alemania

WGK 3

Punto de inflamabilidad F

Not applicable

Punto de inflamabilidad C

Not applicable

Certificado de Análisis

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.